Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy starts working from the first injection, but meaningful weight loss typically becomes noticeable after four to eight weeks of treatment. Most people reach the full therapeutic maintenance dose over several months, and the largest weight reductions seen in clinical trials occurred at 68 weeks. Semaglutide is a prescription-only medicine; a clinician assesses whether it is appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Yes, but the effects are subtle. The 0.25 mg starting dose is there to let your body adjust to semaglutide, not to produce dramatic results straight away. Even so, many people notice a reduction in appetite and fewer cravings within the first week or two. Portions that felt normal before may feel like too much. Hunger between meals tends to quieten down.
What you are less likely to see at this stage is the scale moving significantly. That is expected. The dose is intentionally low, and your body is still adapting to how the medicine slows gastric emptying and signals fullness to the brain. Side effects (nausea is the most common) are also most noticeable in these early weeks, particularly after moving to a higher dose. They generally settle within a few days to a fortnight. The NHS semaglutide medicines page lists what to expect and when to seek advice.
The short answer: Wegovy is working in week one, even if the scales do not yet show it. If you want a closer look at how long before Wegovy takes effect and what is happening in those early weeks, our dedicated page walks through the timeline in detail. Give the titration schedule the time it needs.
For most people, consistent, measurable weight loss starts to appear somewhere between weeks four and eight. This tends to coincide with the move to the 0.5 mg or 1 mg dose, where the appetite-suppressing effect becomes more pronounced and calorie intake drops more reliably.
By weeks twelve to sixteen, many people are at or approaching the 1.7 mg dose, and weight changes become more consistent week to week. If you are curious about how long until Wegovy takes effect, the honest answer is that the pace varies between individuals depending on starting weight, diet, activity levels and how smoothly the titration goes. Thinking about the wider picture of weight management alongside the medicine matters here too.
One thing our prescribers hear regularly is frustration when progress feels slow in month one. It is worth reframing the first eight weeks: the titration phase is building the foundation for the results that follow, not delaying them.
The maintenance dose of 2.4 mg is reached after approximately 16 to 20 weeks of treatment, once the four-step titration is complete. Most of the clinically significant weight reduction happens in the period that follows. In the STEP 1 trial, published in the New England Journal of Medicine, adults on 2.4 mg semaglutide lost an average of around 15% of body weight compared with around 2.4% for placebo, over 68 weeks alongside lifestyle support. The weight loss curve is steepest between roughly weeks 16 and 52, then tends to plateau.
Knowing how long Wegovy takes to work at each dose level can help set realistic expectations from the outset. The approved single-dose 7.2 mg Wegovy pen (approved by the MHRA in April 2026) is the highest available dose for eligible adults with obesity, with trial data suggesting average weight loss of around 20.7% over 72 weeks. This higher maintenance option may be an option for people who have completed the standard titration; any change is a clinical decision made with your prescriber.
For more detail on the duration of treatment itself, our page on how long people typically take Wegovy for weight loss covers what happens when treatment continues and what stopping means for weight over time.
Several factors shape how long semaglutide takes to have an effect for any individual. Starting BMI plays a role: people with a higher starting weight often see a larger absolute reduction in kilograms early on, though percentage weight loss tends to be the more meaningful comparator across different starting points. Adherence to the titration schedule matters. So does diet during treatment, appetite suppression does the heavy lifting, but the quality and composition of what you eat, particularly adequate protein and fibre, influences how well the medicine's effect translates into fat loss rather than lean mass.
Physical activity, sleep quality and stress levels all interact with the biology too, in ways that are still being studied. None of this means the medicine only works if everything else is perfect. It means the effect varies, and that variation is normal. If you feel that semaglutide is not taking effect as expected, that is a conversation for your prescriber, not a reason to adjust the dose yourself. You can read more about the pace at which Wegovy takes effect and what might influence it on our dedicated page. If you are weighing up how this compares to other approaches, our Wegovy overview covers the full picture, including eligibility and how the consultation process works at nume.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.